Discover
VRDN
Viridian Therapeutics, Inc.
18.66
2 x 13.19
2 x 23.48
bid
ask
+
0.32
1.74%
2 @ 04:05 PM
18.89 +0.23 (1.24%)
| Ytd | -40.04% | |
| 1y | -14.44% |
18.16
day range
18.71
13.30
52 week range
33.78
| Open | 18.31 | Prev Close | 18.34 | Low | 18.16 | High | 18.71 | Mkt Cap | 2.11B |
| Vol | 1.33M | Avg Vol | 1.71M | EPS | -3.39 | P/E | N/A | Forward P/E | -6.81 |
| Beta | 1.10 | Short Ratio | 15.89 | Inst. Own | 126.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 21.87 | 200-d Avg | 22.56 | 1yr Est | 36.75 |
| Income Statement | |||
| Total Revenue | 284.00K | ||
| Revenues (USD) | 284.00K | ||
| Gross Profit | 284.00K | ||
| Operating Expenses | 126.55M | ||
| Research and Development Expense | 71.58M | ||
| Selling, General and Administrative Expense | 54.98M | ||
| Operating Income | -126.27M | ||
| Interest Expense | 8.31M | ||
| Net Income | -127.12M | ||
| Net Income Common Stock | -127.12M | ||
| Net Income Common Stock (USD) | -127.12M | ||
| Consolidated Income | -127.12M | ||
| Earnings per Basic Share | -1.05 | ||
| Earnings per Basic Share (USD) | -1.05 | ||
| Earnings per Diluted Share | -1.05 | ||
| Earning Before Interest & Taxes (EBIT) | -118.81M | ||
| Earning Before Interest & Taxes (USD) | -118.81M | ||
| Weighted Average Shares | 107.88M | ||
| Weighted Average Shares Diluted | 107.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 164.99M | ||
| Cash and Equivalents (USD) | 164.99M | ||
| Investments | 816.54M | ||
| Investments Current | 816.54M | ||
| Trade and Non-Trade Receivables | 75.00M | ||
| Current Assets | 1.08B | ||
| Property, Plant & Equipment Net | 4.85M | ||
| Total Assets | 1.10B | ||
| Total Debt | 355.80M | ||
| Current Liabilities | 63.79M | ||
| Debt Non-Current | 355.80M | ||
| Total Liabilities | 435.14M | ||
| Accumulated Retained Earnings (Deficit) | -1.57B | ||
| Accumulated Other Comprehensive Income | -1.15M | ||
| Shareholders Equity | 662.10M | ||
| Shareholders Equity (USD) | 662.10M | ||
| Assets Non-Current | 15.96M | ||
| Total Debt (USD) | 355.80M | ||
| Goodwill and Intangible Assets | 10.00M | ||
| Liabilities Non-Current | 371.34M | ||
| Trade and Non-Trade Payables | 8.65M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 89.00K | ||
| Net Cash Flow from Financing | 325.12M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -11.36M | ||
| Capital Expenditure | -1.31M | ||
| Issuance (Purchase) of Equity Shares | 137.33M | ||
| Issuance (Repayment) of Debt Securities | 187.79M | ||
| Net Cash Flow from Investing | -231.16M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -229.85M | ||
| Net Cash Flow from Operations | -105.32M | ||
| Share Based Compensation | 16.98M | ||